Literature DB >> 25985182

GH Receptor Deficiency in Ecuadorian Adults Is Associated With Obesity and Enhanced Insulin Sensitivity.

Jaime Guevara-Aguirre1, Arlan L Rosenbloom1, Priya Balasubramanian1, Enrique Teran1, Marco Guevara-Aguirre1, Carolina Guevara1, Patricio Procel1, Irene Alfaras1, Rafael De Cabo1, Stefano Di Biase1, Luis Narvaez1, Jannette Saavedra1, Valter D Longo1.   

Abstract

CONTEXT: Ecuadorian subjects with GH receptor deficiency (GHRD) have not developed diabetes, despite obesity.
OBJECTIVE: We sought to determine the metabolic associations for this phenomenon.
DESIGN: Four studies were carried out: 1) glucose, lipid, adipocytokine concentrations; 2) metabolomics evaluation; 3) metabolic responses to a high-calorie meal; and 4) oral glucose tolerance tests.
SETTING: Clinical Research Institute in Quito, Ecuador.
SUBJECTS: Adults homozygous for the E180 splice mutation of the GH receptor (GHRD) were matched for age, gender, and body mass index with unaffected control relatives (C) as follows: study 1, 27 GHRD and 35 C; study 2, 10 GHRD and 10 C; study 3, seven GHRD and 11 C; and study 4, seven GHRD and seven C.
RESULTS: Although GHRD subjects had greater mean percentage body fat than controls, their fasting insulin, 2-hour blood glucose, and triglyceride levels were lower. The indicator of insulin sensitivity, homeostasis model of assessment 2%S, was greater (P < .0001), and the indicator of insulin resistance, homeostasis model of assessment 2-IR, was lower (P = .0025). Metabolomic differences between GHRD and control subjects were consistent with their differing insulin sensitivity, including postprandial decreases of branched-chain amino acids that were more pronounced in controls. High molecular weight and total adiponectin concentrations were greater in GHRD (P = .0004 and P = .0128, respectively), and leptin levels were lower (P = .02). Although approximately 65% the weight of controls, GHRD subjects consumed an identical high-calorie meal; nonetheless, their mean glucose concentrations were lower, with mean insulin levels one-third those of controls. Results of the 2-hour oral glucose tolerance test were similar. MAIN OUTCOME MEASURES: Measures of insulin sensitivity, adipocytokines, and energy metabolites.
CONCLUSIONS: Without GH counter-regulation, GHRD is associated with insulin efficiency and obesity. Lower leptin levels, despite higher percentage body fat, suggest that obesity-associated leptin resistance is GH dependent. Elevated adiponectin levels not correlated with percentage body fat indicate that GH signaling is necessary for their typical suppression with obesity.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25985182      PMCID: PMC4490304          DOI: 10.1210/jc.2015-1678

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  28 in total

Review 1.  Use and abuse of HOMA modeling.

Authors:  Tara M Wallace; Jonathan C Levy; David R Matthews
Journal:  Diabetes Care       Date:  2004-06       Impact factor: 19.112

2.  Branched chain and aromatic amino acids change acutely following two medical therapies for type 2 diabetes mellitus.

Authors:  Geoffrey A Walford; Jaclyn Davis; A Sofia Warner; Rachel J Ackerman; Liana K Billings; Bindu Chamarthi; Rebecca R Fanelli; Alicia M Hernandez; Chunmei Huang; Sabina Q Khan; Katherine R Littleton; Janet Lo; Rita M McCarthy; Eugene P Rhee; Amy Deik; Elliot Stolerman; Andrew Taylor; Margo S Hudson; Thomas J Wang; David Altshuler; Richard W Grant; Clary B Clish; Robert E Gerszten; Jose C Florez
Journal:  Metabolism       Date:  2013-08-15       Impact factor: 8.694

3.  The metabolic phenotype of Prader-Willi syndrome (PWS) in childhood: heightened insulin sensitivity relative to body mass index.

Authors:  Andrea M Haqq; Michael J Muehlbauer; Christopher B Newgard; Steven Grambow; Michael Freemark
Journal:  J Clin Endocrinol Metab       Date:  2010-10-20       Impact factor: 5.958

4.  Adiponectin levels in prepubertal children with Prader-Willi syndrome before and during growth hormone therapy.

Authors:  D A M Festen; A van Toorenenbergen; H J Duivenvoorden; A C S Hokken-Koelega
Journal:  J Clin Endocrinol Metab       Date:  2007-01-30       Impact factor: 5.958

5.  Effects of a combination of rhGH and metformin on adiponectin levels in patients with metabolic syndrome.

Authors:  B L Herrmann; B Saller; M Stratmann; C Berg; K Mann; O E Janssen
Journal:  Horm Metab Res       Date:  2005-01       Impact factor: 2.936

6.  Total and high molecular weight adiponectin are elevated in patients with Laron syndrome despite marked obesity.

Authors:  Hannah Kanety; Rina Hemi; Shira Ginsberg; Clara Pariente; Eleanor Yissachar; Ehud Barhod; Tohru Funahashi; Zvi Laron
Journal:  Eur J Endocrinol       Date:  2009-09-15       Impact factor: 6.664

7.  Growth hormone receptor deficiency in Ecuador: clinical and biochemical phenotype in two populations.

Authors:  J Guevara-Aguirre; A L Rosenbloom; P J Fielder; F B Diamond; R G Rosenfeld
Journal:  J Clin Endocrinol Metab       Date:  1993-02       Impact factor: 5.958

8.  Visceral adipose tissue and metabolic complications of obesity are reduced in Prader-Willi syndrome female adults: evidence for novel influences on body fat distribution.

Authors:  A P Goldstone; E L Thomas; A E Brynes; J D Bell; G Frost; N Saeed; J V Hajnal; J K Howard; A Holland; S R Bloom
Journal:  J Clin Endocrinol Metab       Date:  2001-09       Impact factor: 5.958

9.  Lifetime congenital isolated GH deficiency does not protect from the development of diabetes.

Authors:  Taísa A R Vicente; Ivina E S Rocha; Roberto Salvatori; Carla R P Oliveira; Rossana M C Pereira; Anita H O Souza; Viviane C Campos; Elenilde G Santos; Rachel D C Araújo Diniz; Eugênia H O Valença; Carlos C Epitácio-Pereira; Mario C P Oliveira; Andrea Mari; Manuel H Aguiar-Oliveira
Journal:  Endocr Connect       Date:  2013-06-15       Impact factor: 3.335

10.  Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance.

Authors:  Ele Ferrannini; Andrea Natali; Stefania Camastra; Monica Nannipieri; Andrea Mari; Klaus-Peter Adam; Michael V Milburn; Gabi Kastenmüller; Jerzy Adamski; Tiinamaija Tuomi; Valeriya Lyssenko; Leif Groop; Walter E Gall
Journal:  Diabetes       Date:  2012-11-16       Impact factor: 9.461

View more
  20 in total

1.  Adipocyte JAK2 mediates growth hormone-induced hepatic insulin resistance.

Authors:  Kevin C Corbit; João Paulo G Camporez; Jennifer L Tran; Camella G Wilson; Dylan A Lowe; Sarah M Nordstrom; Kirthana Ganeshan; Rachel J Perry; Gerald I Shulman; Michael J Jurczak; Ethan J Weiss
Journal:  JCI Insight       Date:  2017-02-09

2.  Brain Structure and Function Associated with Younger Adults in Growth Hormone Receptor-Deficient Humans.

Authors:  Kaoru Nashiro; Jaime Guevara-Aguirre; Meredith N Braskie; George W Hafzalla; Rico Velasco; Priya Balasubramanian; Min Wei; Paul M Thompson; Mara Mather; Marvin D Nelson; Alexandra Guevara; Enrique Teran; Valter D Longo
Journal:  J Neurosci       Date:  2017-01-10       Impact factor: 6.167

Review 3.  The enigmatic role of growth hormone in age-related diseases, cognition, and longevity.

Authors:  Gabriela Colon; Tatiana Saccon; Augusto Schneider; Marcelo B Cavalcante; Derek M Huffman; Darlene Berryman; Ed List; Yuji Ikeno; Nicolas Musi; Andrzej Bartke; John Kopchick; James L Kirkland; Tamara Tchkonia; Michal M Masternak
Journal:  Geroscience       Date:  2019-09-04       Impact factor: 7.713

4.  Imaging mass spectrometry demonstrates age-related decline in human adipose plasticity.

Authors:  Christelle Guillermier; Pouneh K Fazeli; Soomin Kim; Mingyue Lun; Jonah P Zuflacht; Jessica Milian; Hang Lee; Hugues Francois-Saint-Cyr; Francois Horreard; David Larson; Evan D Rosen; Richard T Lee; Claude P Lechene; Matthew L Steinhauser
Journal:  JCI Insight       Date:  2017-03-09

Review 5.  GH and ageing: Pitfalls and new insights.

Authors:  Andrzej Bartke; Justin Darcy
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2017-02-24       Impact factor: 4.690

6.  Developments in our understanding of the effects of growth hormone on white adipose tissue from mice: implications to the clinic.

Authors:  Darlene E Berryman; Brooke Henry; Rikke Hjortebjerg; Edward O List; John J Kopchick
Journal:  Expert Rev Endocrinol Metab       Date:  2016-02-24

Review 7.  Effect of growth hormone on insulin signaling.

Authors:  Rita Sharma; John J Kopchick; Vishwajeet Puri; Vishva M Sharma
Journal:  Mol Cell Endocrinol       Date:  2020-09-20       Impact factor: 4.102

Review 8.  Mouse models of growth hormone deficiency.

Authors:  Edward O List; Reetobrata Basu; Silvana Duran-Ortiz; Jackson Krejsa; Elizabeth A Jensen
Journal:  Rev Endocr Metab Disord       Date:  2020-10-09       Impact factor: 6.514

Review 9.  Extending lifespan by modulating the growth hormone/insulin-like growth factor-1 axis: coming of age.

Authors:  Silvana Duran-Ortiz; Edward O List; Reetobrata Basu; John J Kopchick
Journal:  Pituitary       Date:  2021-01-18       Impact factor: 4.107

Review 10.  Insights from the clinical phenotype of subjects with Laron syndrome in Ecuador.

Authors:  Jaime Guevara-Aguirre; Camila Bautista; Carlos Torres; Gabriela Peña; Carolina Guevara; Cristina Palacios; Alexandra Guevara; Antonio W D Gavilanes
Journal:  Rev Endocr Metab Disord       Date:  2020-10-12       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.